CD274 and non-small cell lung carcinoma: Although there are many studies on the prognosis of ICIs-based therapy in NSCLC, there are many factors affecting ICI immunotherapy, involving various clinical factors and genetic mutations in patients, especially for patients with PD-L1 TPS > 1.